Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-05-04 | Dr. Daniel earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital. |
| 2017-04-28 | Dr. Daniel has more than 16 years of experience in biopharmaceutical discovery and development. He is currently Chairman of Vividion Therapeutics, is a venture partner at ARCH Venture Partners, and serves as a director of JUNO Therapeutics, Inc., Magenta Therapeutics, Inc., and VIR Biotechnology, Inc. |
| 2018-04-18 | Dr. Daniel has more than 16 years of experience in biopharmaceutical discovery and development. He is currently Chairman of Vividion Therapeutics, Inc., is a venture partner at ARCH Venture Partners, and serves as a director of ImmusanT, Inc., Gossamer Bio, Inc., Magenta Therapeutics, Inc., and VIR Biotechnology, Inc. Previously, he was Chairman of Research at Celgene Corporation, and served as President of Research and Early Development from December 2006 until February 2012, and as Executive Vice President and President of Research and Early Development until December 2015. Prior to Celgene, he served as Chief Scientific Officer and Director at Ambrx Inc., from August 2003 to November 2006. Dr. Daniel also served as Vice President of Research at Amgen from August 2002 to April 2003, where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Prior to Amgen’s acquisition of Immunex Corporation, Dr. Daniel served as Senior Vice President of Discovery Research at Immunex from May 2000 to August 2002. Dr. Daniel has been a member of the Therapeutic Advisory Board of aTyr Pharma, Inc. since March 2011, and advises BlackThorn Therapeutics, Inc. a privately-held biotechnology company. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center. A nephrologist and former academic investigator, Dr. Daniel was previously the C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. He formerly conducted research in the Howard Hughes Medical Institute at UC San Francisco, earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital. |
| 2019-04-26 | Dr. Daniel earned an M.D. from the University of Texas, Southwestern, and has held senior leadership roles in biopharmaceutical companies. |
| 2020-08-19 | Thomas O. Daniel 9,550 * |
| 2021-04-14 | Dr. Daniel holds an M.D. and has held senior leadership roles in biopharmaceutical companies such as Celgene and Amgen. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-19